Literature DB >> 19261747

Inactivation of p53 and Pten promotes invasive bladder cancer.

Anna M Puzio-Kuter1, Mireia Castillo-Martin, Carolyn W Kinkade, Xi Wang, Tian Huai Shen, Tulio Matos, Michael M Shen, Carlos Cordon-Cardo, Cory Abate-Shen.   

Abstract

Although bladder cancer represents a serious health problem worldwide, relevant mouse models for investigating disease progression or therapeutic targets have been lacking. We show that combined deletion of p53 and Pten in bladder epithelium leads to invasive cancer in a novel mouse model. Inactivation of p53 and PTEN promotes tumorigenesis in human bladder cells and is correlated with poor survival in human tumors. Furthermore, the synergistic effects of p53 and Pten deletion are mediated by deregulation of mammalian target of rapamycin (mTOR) signaling, consistent with the ability of rapamycin to block bladder tumorigenesis in preclinical studies. Our integrated analyses of mouse and human bladder cancer provide a rationale for investigating mTOR inhibition for treatment of patients with invasive disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261747      PMCID: PMC2661614          DOI: 10.1101/gad.1772909

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  38 in total

Review 1.  Urothelial tumorigenesis: a tale of divergent pathways.

Authors:  Xue-Ru Wu
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

2.  Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.

Authors:  Maria Y Wang; Kan V Lu; Shaojun Zhu; Ederlyn Q Dia; Igor Vivanco; Gregory M Shackleford; Webster K Cavenee; Ingo K Mellinghoff; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

3.  Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo.

Authors:  Hans-Guido Wendel; Abba Malina; Zhen Zhao; Lars Zender; Scott C Kogan; Carlos Cordon-Cardo; Jerry Pelletier; Scott W Lowe
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

4.  The coordinate regulation of the p53 and mTOR pathways in cells.

Authors:  Zhaohui Feng; Haiyan Zhang; Arnold J Levine; Shengkan Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-31       Impact factor: 11.205

5.  Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients.

Authors:  Hiroshi Tsuruta; Hiroyuki Kishimoto; Takehiko Sasaki; Yasuo Horie; Miyuki Natsui; Yoshiko Shibata; Koichi Hamada; Nobuyuki Yajima; Koichi Kawahara; Masato Sasaki; Norihiko Tsuchiya; Katsuhiko Enomoto; Tak Wah Mak; Toru Nakano; Tomonori Habuchi; Akira Suzuki
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

Review 6.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.

Authors:  Megan Cully; Han You; Arnold J Levine; Tak W Mak
Journal:  Nat Rev Cancer       Date:  2006-03       Impact factor: 60.716

7.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Authors:  Zhenbang Chen; Lloyd C Trotman; David Shaffer; Hui-Kuan Lin; Zohar A Dotan; Masaru Niki; Jason A Koutcher; Howard I Scher; Thomas Ludwig; William Gerald; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

Review 8.  The pathology of bladder cancer.

Authors:  Victor E Reuter
Journal:  Urology       Date:  2006-03       Impact factor: 2.649

9.  Pten deficiency activates distinct downstream signaling pathways in a tissue-specific manner.

Authors:  Lina I Yoo; David W Liu; Sandrine Le Vu; Roderick T Bronson; Hong Wu; Junying Yuan
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

Review 10.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

View more
  141 in total

1.  Mouse models of human bladder cancer as a tool for drug discovery.

Authors:  Catherine Seager; Anna M Puzio-Kuter; Carlos Cordon-Cardo; James McKiernan; Cory Abate-Shen
Journal:  Curr Protoc Pharmacol       Date:  2010-06

Review 2.  Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.

Authors:  David D Chism; Michael E Woods; Matthew I Milowsky
Journal:  Oncologist       Date:  2013-07-24

Review 3.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

Authors:  Katarzyna Marcinkiewicz; Kymora B Scotland; Stephen A Boorjian; Emeli M Nilsson; Jenny Liao Persson; Per Anders Abrahamsson; Cinzia Allegrucci; Ieuan A Hughes; Lorraine J Gudas; Nigel P Mongan
Journal:  Int J Oncol       Date:  2011-09-28       Impact factor: 5.650

4.  Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.

Authors:  Antoine Italiano; Chun-Liang Chen; Rachael Thomas; Matthew Breen; Françoise Bonnet; Nicolas Sevenet; Michel Longy; Robert G Maki; Jean-Michel Coindre; Cristina R Antonescu
Journal:  Cancer       Date:  2012-05-30       Impact factor: 6.860

5.  ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.

Authors:  Tomasz B Owczarek; Takashi Kobayashi; Ricardo Ramirez; Lijie Rong; Anna M Puzio-Kuter; Gopa Iyer; Min Yuen Teo; Francisco Sánchez-Vega; Jingqiang Wang; Nikolaus Schultz; Tian Zheng; David B Solit; Hikmat A Al-Ahmadie; Cory Abate-Shen
Journal:  Cancer Res       Date:  2017-01-12       Impact factor: 12.701

6.  The role of WNT signalling in urothelial cell carcinoma.

Authors:  I Ahmad
Journal:  Ann R Coll Surg Engl       Date:  2015-08-14       Impact factor: 1.891

7.  Implication of androgen receptor in urinary bladder cancer: a critical mini review.

Authors:  Arshad H Rahmani; Mohammad Alzohairy; Ali Yousif Y Babiker; Amjad A Khan; Salah M Aly; Moshahid A Rizvi
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

Review 8.  Emerging personalized approaches for the management of advanced urothelial carcinoma.

Authors:  Che-Kai Tsao; Benjamin A Gartrell; William K Oh; Matthew D Galsky
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

9.  mTORC1 and p53: clash of the gods?

Authors:  Paul Hasty; Zelton Dave Sharp; Tyler J Curiel; Judith Campisi
Journal:  Cell Cycle       Date:  2013-01-01       Impact factor: 4.534

Review 10.  Urothelial carcinoma: stem cells on the edge.

Authors:  William D Brandt; William Matsui; Jonathan E Rosenberg; Xiaobing He; Shizhang Ling; Edward M Schaeffer; David M Berman
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.